From (MedPage Today) — An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with…
Read More
Is it possible for a GLP-1 agonist to enhance the symptoms of Parkinson’s disease?
